Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (US20190038735) VLP-BASED VACCINES FOR TARGETING STAPHYLOCOCCUS AUREUS SECRETED VIRULENCE FACTORS

Office : United States of America
Application Number: 16074886 Application Date: 01.02.2017
Publication Number: 20190038735 Publication Date: 07.02.2019
Publication Kind : A1
Prior PCT appl.: Application Number:PCTUS2017015960 ; Publication Number: Click to see the data
IPC:
A61K 39/085
A61P 31/04
A61P 37/04
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
085
Staphylococcus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
04
Immunostimulants
CPC:
A61K 2039/52
A61K 39/085
A61P 31/04
A61P 37/04
Applicants: STC.UNM
Inventors: Pamela Hall
Bryce Chackerian
David S. Peabody
Seth Michael Daly
Bradley Owen Elmore
Kathleen Triplett
Priority Data:
Title: (EN) VLP-BASED VACCINES FOR TARGETING STAPHYLOCOCCUS AUREUS SECRETED VIRULENCE FACTORS
Abstract: front page image
(EN)

The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.


Also published as:
WO/2017/136400